Strategies for Managing Cytopenias and Infection Prophylaxis with CAR-T Therapy
The conversation examines adverse events beyond CRS and neurotoxicities in CAR-T therapy, focusing on strategies for managing prolonged cytopenias, infection prophylaxis, and unique adverse events associated with ide-cel and cilta-cel.
Video content above is prompted by the following:
- Beyond CRS and neurotoxicities, are there other adverse events that require particular attention?
- How do you address prolonged cytopenias following CAR-T infusion?
- What is your approach to infection prophylaxis and management in these patients?
- Are there any distinct adverse events associated specifically with ide-cel or cilta-cel that clinicians should be aware of?
Recent Videos
Related Content
